

Alastair Peter Greystoke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1996884/publications.pdf>

Version: 2024-02-01

45
papers

4,085
citations

304602

22
h-index

265120

42
g-index

46
all docs

46
docs citations

46
times ranked

6496
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1556-1563.	0.8	788
2	Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 525-532.	0.8	755
3	Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. <i>Nature Medicine</i> , 2014, 20, 897-903.	15.2	608
4	Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy. <i>American Journal of Pathology</i> , 2009, 175, 808-816.	1.9	223
5	Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 120, 461-467.	1.1	191
6	ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2017, 12, 1357-1367.	0.5	144
7	Update on tubulin-binding agents. <i>Pathologie Et Biologie</i> , 2006, 54, 72-84.	2.2	134
8	Biomarker method validation in anticancer drug development. <i>British Journal of Pharmacology</i> , 2008, 153, 646-656.	2.7	114
9	A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2011, 104, 750-755.	2.9	113
10	Biomarkers of apoptosis. <i>British Journal of Cancer</i> , 2008, 99, 841-846.	2.9	101
11	First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. <i>Clinical Cancer Research</i> , 2015, 21, 3412-3419.	3.2	101
12	The National Lung Matrix Trial of personalized therapy in lung cancer. <i>Nature</i> , 2020, 583, 807-812.	13.7	96
13	Isolation and Extraction of Circulating Tumor DNA from Patients with Small Cell Lung Cancer. <i>Annals of the New York Academy of Sciences</i> , 2008, 1137, 98-107.	1.8	90
14	Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis. <i>Journal of Thoracic Oncology</i> , 2020, 15, 637-648.	0.5	83
15	Optimisation of circulating biomarkers of cell death for routine clinical use. <i>Annals of Oncology</i> , 2008, 19, 990-995.	0.6	68
16	A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2019, 120, 975-981.	2.9	61
17	Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. <i>British Journal of Cancer</i> , 2011, 104, 719-725.	2.9	48
18	Alternative splicing in lung cancer. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2019, 1862, 194388.	0.9	47

#	ARTICLE	IF	CITATIONS
19	The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-small Cell Lung Cancer and in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 474-484.	1.0	41
20	Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer. <i>Journal of Medical Economics</i> , 2018, 21, 113-121.	1.0	30
21	A Pilot Study Assessing the Prognostic Value of CK18 and nDNA Biomarkers in Severe Sepsis Patients. <i>Clinical Drug Investigation</i> , 2012, 32, 179-187.	1.1	25
22	Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 540-552.	5.1	25
23	A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 6284-6294.	3.2	24
24	Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours. <i>British Journal of Cancer</i> , 2004, 91, 1651-1655.	2.9	23
25	Development of a circulating miRNA assay to monitor tumor burden: From mouse to man. <i>Molecular Oncology</i> , 2016, 10, 282-291.	2.1	18
26	SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. <i>British Journal of Cancer</i> , 2017, 117, 938-946.	2.9	18
27	Biomarkers of cell death applicable to early clinical trials. <i>Experimental Cell Research</i> , 2012, 318, 1252-1259.	1.2	17
28	Spindle cell carcinoma of the head and neck region: treatment and outcomes of 15 patients. <i>Ecancermedalscience</i> , 2015, 9, 594.	0.6	17
29	Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 111, 51-58.	0.9	15
30	Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis. <i>Targeted Oncology</i> , 2022, 17, 153-166.	1.7	15
31	Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours. <i>British Journal of Cancer</i> , 2020, 123, 1360-1369.	2.9	10
32	A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2016, 68, 1-10.	1.3	9
33	A phase II trial of abemaciclib in patients with p16ink4a negative, relapsed mesothelioma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8558-8558.	0.8	7
34	A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2593-2593.	0.8	7
35	Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer. <i>British Journal of Cancer</i> , 2022, 126, 1157-1167.	2.9	7
36	The use of circulating biomarkers in early clinical trials in patients with cancer. <i>Biomarkers in Medicine</i> , 2015, 9, 1011-1023.	0.6	2

#	ARTICLE	IF	CITATIONS
37	An introduction to stratified medicine. <i>Drug Discovery Today</i> , 2015, 20, 1409-1413.	3.2	2
38	An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS9138-TPS9138.	0.8	2
39	TARGET National: A U.K.-wide liquid-based molecular profiling program to enhance recruitment to early-phase trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS3163-TPS3163.	0.8	2
40	Hypofractionated chemoradiotherapy for locally advanced non-small cell lung cancer: Is split-dose chemotherapy safer than full dose chemotherapy?. <i>Radiotherapy and Oncology</i> , 2021, 154, e13.	0.3	1
41	P-OGC20â€œCan prehabilitation prevent development of sarcopenia during neoadjuvant chemotherapy for oesophagogastric adenocarcinoma?. <i>British Journal of Surgery</i> , 2021, 108, .	0.1	1
42	Atezolizumab and bevacizumab in patients with relapsed mesothelioma: MIST4â€œa phase IIa trial with cellular and molecular correlates of efficacy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8560-8560.	0.8	1
43	Serum biomarkers of apoptosis. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 115-127.	2.2	0
44	Sequential chemotherapy followed by radical thoracic radiotherapy (50 Gy in 25 fractions) in limited stage small cell lung cancer. <i>Ecancermedalscience</i> , 2020, 14, 1019.	0.6	0
45	Re-evaluating Subsequent Treatment Options in Non-small Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors. <i>Clinical Oncology</i> , 2022, , .	0.6	0